Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03915925 · ClinicalTrials.gov registry record

Short-term Clinical Deterioration After Acute Pulmonary Embolism

A clinical trial of Pulmonary Embolism, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
935
Enrollment target
6
Study locations

NCT03915925 is a study of Pulmonary Embolism that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 935 participants, below the 3,039-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03915925, a study of Pulmonary Embolism, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
935 participants
Enrollment target
6
Study locations

Study Summary

This is a prospective, observational, multicenter cohort study to compare right ventricular dysfunction dependent and independent prognostic models for short-term serous adverse events in patients who are diagnosed with pulmonary embolism in the emergency department. Clinical endpoints are assessed at days 1-5. A thirty-day follow-up phone call is conducted to obtain further clinical endpoints and a quality of life assessment.

Conditions Studied

Study Locations (6)

California

  • San Diego Medical Center - San Diego

Delaware

  • Christiana Care Health System - Newark

Florida

  • Orlando Regional Medical Center - Orlando

North Carolina

  • Carolinas Medical Center - Main - Charlotte

Tennessee

  • Vanderbilt Medical Center - Nashville

Utah

  • Univeristy of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 935 participants
Start Date 2018-09-30
Est. Completion 2020-11-30

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT03915925

The ClinicalTrials.gov registry entry for NCT03915925 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 935 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,039-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (69% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 0 interventions.

NCT03915925 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Delaware, Florida.

Frequently Asked Questions

What is clinical trial NCT03915925 about?

NCT03915925 is a clinical study titled "Short-term Clinical Deterioration After Acute Pulmonary Embolism". This is a prospective, observational, multicenter cohort study to compare right ventricular dysfunction dependent and independent prognostic models for short-term serous adverse events in patients who are diagnosed with pulmonary embolism in the emergency department. Clinical endpoints are assessed ...

What is the current status of trial NCT03915925?

This trial is currently completed. The enrollment target is 935 participants. The study started on 2018-09-30. Estimated completion is 2020-11-30.

What conditions does trial NCT03915925 study?

This clinical trial studies the following conditions: Pulmonary Embolism.

Who is sponsoring clinical trial NCT03915925?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03915925 being conducted?

This trial has 6 study locations across California, Delaware, Florida, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.